# PhageLab Chile SpA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phagelab-chile

- Industry: Biotechnology
- Headquarters: Santiago, Chile
- Website: www.phage-lab.com
- Total disclosed funding: $4M
- Latest round: Seed (Jun 1, 2018)
- Investors on record: 1

## About

Based in Chile, PhageLab Chile SpA operates as a biotechnology company specializing in developing bacteriophage-based solutions to combat bacterial pathogens in livestock, enhancing animal health and farm productivity.Founded in 2010 and headquartered in Santiago, Chile, PhageLab Chile SpA focuses on biotechnology solutions using bacteriophages. The company has successfully completed three funding deals, with the most recent occurring on January 23, 2024, where it raised USD 11.000 mn from investors including Collaborative Fund, Nazca, and Water Lemon Ventures. The founding team consists of Diego Belmar, Hans Pieringer, and Pablo Palma, with Hans Pieringer currently serving as CEO.PhageLab specializes in developing innovative solutions utilizing bacteriophages, which are natural viruses that specifically target and eliminate bacterial pathogens. The company’s core offerings include customized bacteriophage cocktails tailored to combat specific bacterial infections affecting livestock and poultry, ultimately enhancing animal health and farm productivity. Their products are underpinned by a robust machine-learning approach that allows for the selection and optimization of bacteriophage combinations to effectively inhibit harmful bacteria. PhageLab’s clientele primarily consists of livestock and poultry producers across various geographical markets, including Latin America, with notable customer presence in Chile, Brazil, and the broader Southern Cone region. The non-invasive diagnostic protocols employed by PhageLab ensure that disease detection does not disrupt operational continuity for producers, thereby supporting efficient and sustainable agricultural practices.PhageLab's revenue model is built around partnerships and B2B transactions with livestock and poultry producers. Revenue is generated through the sale of bacteriophage cocktails and associated consulting services that facilitate the application of these products in the field. Clients typically engage with PhageLab through structured agreements that may involve initial diagnosis followed by the provision of tailored phage solutions, ensuring ongoing support and optimization of animal health management strategies. The company’s flagship products, such as INSPEKTOR and FÓRMIDA, are integral to these transactions, where clients receive comprehensive solutions that include both the bacteriophage treatments and the necessary training for application. The structured approach to client engagement fosters long-term partnerships, which are essential for driving revenue and sustaining growth in the competitive agricultural biotechnology market.In January 2024, PhageLab Chile SpA raised USD 11.000 mn in venture funding from new investors Water Lemon Ventures, Collaborative Fund, and Nazca. The company will use this funding to support its expansion into Brazil and the US markets.

## Funding rounds

- Seed, Jun 1, 2018, $4M — Invexor Venture Partners

## Investors

- Invexor Venture Partners (https://capitalatlas.ai/funds/invexor-venture-partners) — Seed